About Ipsa
Ipsa is a venture capital firm founded in 1986. It is primarily based out of Hayward, United States. As of Apr 2009, Ipsa has invested in 10 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Consumer. Most recently it participated in the $***** Series B round of SpineGuard Overall, Ipsa portfolio has seen 4 IPOs and 3 acquisitions including key companies like MDxHealth, Immutep and SpineGuard. A lot of funds co-invest with Ipsa, with names like A Plus Finance sharing a substantial percentage of its portfolio. Ipsa has team of 2 people including 2 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B
Portfolio IPOs
Portfolio Acquisitions
Ipsa's List of Top Investments
Ipsa has a portfolio of 10 companies. Their most notable investmentis in SpineGuardTheir portfolio spans across France, United States, Australia and 3 more locations. They have invested in Life Sciences, High Tech, Consumer and 6 other sectors, across stages such as Series B stage. Here is the list of top investments by Ipsa:1. MDxHealth
Provider of epigenetic tests for personalized cancer assessment and treatment. Its flagship product ConfirmMDx uses the proprietary DNA methylation platform and biomarkers to assess the need for future biopsies in patients otherwise clear of prostrate cancer. Another closely related product SelectMDx predicts the risk of aggressive cancer using RT-PCR on urine samples to estimate levels of prostrate specific antigens.
Key facts about MDxHealth
- Founded Year: 2003
- Location: Irvine (United States)
- Annual Revenue: $5M - $25M as on Aug 15, 2022
- Stage: Public
- Employee Count: 318 as on Aug 31, 2026
- Investors: Kreos Capital, Eiffel Investment Group and 13 Others
- Latest Funding Round: Post IPO, Apr 27, 2020, $*****
- Highlight: Public
2. Immutep
Developer of immunotherapies for the treatment of cancer and autoimmune diseases. The company's product line include Eftilagimod alpha for metastatic cancers, IMP761, a humanized IgG4 monoclonal antibody for immunological diseases, and LAG525 for autoimmune diseases.
Key facts about Immutep
- Founded Year: 2001
- Location: Sydney (Australia)
- Stage: Acquired
- Employee Count: 57 as on Aug 31, 2026
- Investors: Ridgeback Capital Management, ARC and 4 Others
- Latest Funding Round: Post IPO, Jun 21, 2021, $*****
- Highlight: Acquired
3. SpineGuard
Innovating spine surgery with real-time sensing technology for safer implant placement. They are dedicated to making spine surgery safer through their Dynamic Surgical Guidance (DSG) technology. Their handheld devices provide real-time alerts to surgeons, preventing vertebral cortical wall breaches. DSG technology measures electrical conductivity of tissues, eliminating the need for radiation. They focus on secure and streamlined skeletal implant placement, benefiting patients, surgeons, and healthcare providers. They offer solutions for pedicle screw placement accuracy, reduced radiation exposure, and complex deformity cases. They collaborate with medical device companies to expand the application of their DSG platform. They are committed to Corporate Social Responsibility, focusing on environment, sustainable procurement, labor & human rights, and ethics. Their products are registered in numerous countries and approved by regulatory bodies. They aim to establish DSG as a standard of care in skeletal implant placement.
Key facts about SpineGuard
- Founded Year: 2009
- Location: San Francisco (United States)
- Stage: Public
- Total Funding till date: $21.2M
- Employee Count: 23 as on Aug 31, 2026
- Investors: IPF Partners, Ipsa and 5 Others
- Latest Funding Round: Post IPO, Apr 06, 2017, $*****
- Highlight: Public
4. Symbio
Manufacturer of hydrogen fuel cell systems for mobility and industry. The company develops and produces integrated hydrogen fuel cell systems for electrifying mobility and stationary applications. It offers a range of StackPack systems. The company aims to advance zero-emission hydrogen mobility by developing a circular ecosystem.
Key facts about Symbio
- Founded Year: 2010
- Location: Paris (France)
- Stage: Series B
- Employee Count: 538 as on Aug 31, 2026
- Investors: BNP Paribas, Societe Generale and 10 Others
- Latest Funding Round: Conventional Debt, Jan 04, 2024, $*****
5. Club Cooee
Club Cooee is a 3D chat community. Users can chat, plan party, run music clubs, quiz, and sell their creations and hang out with friends. Claims to be backed by venture investors Aurelia Private Equity, Generis Capital Partners, IPSA and ISB.
Key facts about Club Cooee
- Founded Year: 2007
- Location: Kaiserslautern (Germany)
- Stage: Series A
- Employee Count: 19 as on Aug 31, 2026
- Investors: Ipsa, Innoven Partners and 4 Others
- Latest Funding Round: Series A, Oct 27, 2010, $*****
Ipsa's Investments by Stage
Ipsa has made 1 investment in Series B stage with an average round size of $11M.Ipsa's Investments by Sector
Ipsa has a portfolio focused on Life Sciences. Notably, it has invested in 7 Enterprise (B2B) companies, 7 Tech companies, 2 Consumer (B2C) companies and at least 2 companies focusing on Social impact.Ipsa's Investments by Geography
Ipsa has made most investments in United States (1).Ipsa's recent investments
Ipsa has not made any investment in 2026 so far.Here are the most recent investments by Ipsa:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 09, 2009 | United States | Series B | 3086 | [+1] |
IPOs and Publicly Listed companies in Ipsa's Portfolio
4 of Ipsa's portfolio companies have become public. EyeGate got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Feb 2015 at marketcap of $38M and SpineGuard got listed on the Euronext Exchange (Euronext) at marketcap of $52.1M.Here are Ipsa's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 13, 2015 | - | - | 5269 | |
Apr 29, 2013 | Apr 09, 2009 | Series B | 9114 | |
Oct 24, 2007 | - | - | 1699 | |
Jun 30, 2006 | - | - | 5824 |
Acquired companies in Ipsa's Portfolio
3 companies from Ipsa's portfolio have been acquired. The most recent acquisition was CMC Biologics in Dec 2016 by AGC for $*****.Here are Ipsa's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 15, 2016 | - | - | 2654 | |
Oct 02, 2014 | - | - | 8936 | |
May 27, 2014 | - | - | 5391 |
Team profile of Ipsa
Ipsa has a team of 2 members including 2 Partners located in France. Ipsa's team does not sit on the board of any company as of now.Co-investors of Ipsa
Over the past 17 years, 6 investors have co-invested in Ipsa's portfolio companies. This includes funds and angels.
- Top Co-investors of Ipsa: 2 investors entered a company along with Ipsa. These include investors like A Plus Finance (1 company).
- Invested after Ipsa: A total of 4 investors have invested in Ipsa's portfolio after their investments. Top Investors include Delta Partners (1 company), IPF Partners (1 company) and Bpifrance (1 company).
